Fortress Biotech vs Rockwell Medical
FBIO and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FBIO and RMTI compare
Fortress Biotech is the larger company, worth 2.3 times as much as Rockwell Medical ($62.9M against $27.2M).
Fortress Biotech grew revenue faster over the last twelve months (15.5% versus −21.1% for Rockwell Medical).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −7.3% at Rockwell Medical.
Rockwell Medical scores higher on the StockData Score (11 against 9 for Fortress Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FBIO | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $62.9M | $27.2M |
| Share price | $1.71 | $6.76 |
| Change, 1 year | −31.3% | −25.9% |
| Change, 5 years | −96.0% | −86.0% |
| Beta (5Y) | 0.72 | −0.02 |
| Employees | 78 | 157 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 4 | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× | 0.4× (better) |
| P/B | 0.4× (better) | 0.8× |
| P/FCF | – | 17.7× |
| FCF yield | – | 5.7% |
| Fair value | – | $33.27 |
| Margin of safety | – | 79.7% |
| Growth | ||
| Revenue growth (TTM) | 15.5% (better) | −21.1% |
| Revenue growth, 5Y average | 6.8% (better) | 2.2% |
| Profitability | ||
| Gross margin | 65.6% (better) | 17.7% |
| Operating margin | −42.9% | −6.5% (better) |
| Net margin | 163% (better) | −7.3% |
| FCF margin | – | 2.2% |
| Return on equity | 107% (better) | −15.5% |
| Return on invested capital | −261% | −17.9% (better) |
| Financial health | ||
| Debt / equity | 0.21 (better) | 0.26 |
| Interest coverage | −3.0× (better) | −4.0× |
| Current ratio | 3.96 (better) | 3.25 |
| Altman Z-score | −1.81 (better) | −7.79 |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.9% | 0.05% |
| Held by insiders | 31.6% | 100% |
| Insider net buying, 12 months | – | −$11.6K |
Go deeper
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.